Home・Список акций・Coherus Oncology Inc

Coherus Oncology Inc

Закрыт

СекторЗдравоохранение

1.25 -14.38

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.12

Макс.

1.44

Ключевые показатели
By Trading Economics
Доход	-279M -38M
Продажи	-438K 12M
P/E Средняя по отрасли	3.509 68.51
Прибыль на акцию	-0.25
Рентабельность продаж	-308.197
Сотрудники	145
EBITDA	9.3M -34M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+468.97% upside

Дивиденды
By Acuity
Следующий отчет о доходах	5 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-37M 222M
Предыдущая цена открытия	15.63
Предыдущая цена закрытия	1.25

Новостные настроения

By Acuity

13%

87%

22 / 340 Рейтинг в Healthcare

Coherus Oncology Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

6 авг. 2026 г., 23:21 UTC

Coherus BioSciences Inc shares fell in after-market trading, reflecting ongoing weakness and volatility amid a lack of specific news to explain the decline.

5 авг. 2026 г., 23:01 UTC

News

Coherus BioSciences shares are lower in after-market trading following a second-quarter adjusted EPS of -$0.19, despite exceeding estimates. Sales missed expectations at $14.31 million.

4 авг. 2026 г., 23:56 UTC

Coherus BioSciences Inc shares are higher in after-market hours, reflecting strong demand since Tuesday's close amid a narrowing U.S. trade deficit.

3 авг. 2026 г., 19:44 UTC

Coherus BioSciences Inc shares are higher during Monday's session, continuing a notable advance since Friday's close, despite trading below its 20-day moving average.

31 июл. 2026 г., 20:06 UTC

Coherus BioSciences shares are lower today, amid rising U.S. Treasury yields and crude oil prices, which have heightened inflation concerns and interest rate expectations.

30 июл. 2026 г., 22:46 UTC

Coherus BioSciences Inc shares are higher in after-market trading, reflecting a positive response amid broader market recovery despite no specific company news identified.

29 июл. 2026 г., 18:46 UTC

Macro Event

Coherus BioSciences Inc shares are lower today amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

27 июл. 2026 г., 17:31 UTC

Coherus BioSciences Inc shares are higher during Monday's session, reflecting broader market trends amid declining oil prices that have eased inflation concerns.

23 июл. 2026 г., 19:56 UTC

Coherus BioSciences Inc is trading lower amid broader market concerns over corporate earnings and inflation pressures. Shares remain below their 20-day moving average.

22 июл. 2026 г., 18:26 UTC

Coherus BioSciences Inc shares are trading lower amid broader market pressures, remaining near the lower end of their one-month range. No specific news was identified.

21 июл. 2026 г., 19:41 UTC

Social Media

Coherus BioSciences Inc shares are higher as analysts set a $7 average price target, with potential for positive data readouts this month.

20 июл. 2026 г., 17:31 UTC

Coherus BioSciences Inc. shares are roughly flat today, showing little change since Friday's close amid routine trading activity within a one-month range.

Сравнение c конкурентами

Изменение цены

Coherus Oncology Inc Прогноз

Целевая цена

By TipRanks

468.97% рост

Прогноз на 12 месяцев

Средняя 8.25 USD 468.97%

Максимум 12 USD

Минимум 4 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Coherus Oncology Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

Покупка

Удержание

Продажа

Основано на мнении 5 аналитиков, присваивавших рейтинги акциям Coherus Oncology Inc – Данные за последние 3 месяца.

Настроения

By Acuity

22 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.